134 related articles for article (PubMed ID: 38265378)
1. Association of CirAEs and Efficacy in NSCLC Patients Treated with PD-1/PD-L1: A Meta-analysis of Cohort Studies.
Lu J; Zhu J; Jiang G
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38265378
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Wang C; Yu X; Wang W
Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
[TBL] [Abstract][Full Text] [Related]
6. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhuansun Y; Huang F; Du Y; Lin L; Chen R; Li J
J Thorac Dis; 2017 Mar; 9(3):655-665. PubMed ID: 28449473
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
14. The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.
Li S; Zhang S; Liu J; Yang C; Zhang L; Cheng Y
J Thorac Dis; 2019 Nov; 11(11):4453-4463. PubMed ID: 31903233
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
17. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
Zheng QM; Li YY; Wang YP; Li GX; Zhao MM; Sun ZG
Expert Rev Anticancer Ther; 2023 Jun; 23(6):643-659. PubMed ID: 37114477
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
[TBL] [Abstract][Full Text] [Related]
19. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Cui P; Huang D; Wu Z; Tao H; Zhang S; Ma J; Liu Z; Wang J; Huang Z; Chen S; Zheng X; Hu Y
Ther Adv Med Oncol; 2020; 12():1758835920922033. PubMed ID: 32426052
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]